PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT285
EST. COMPLETION2027-05-18

Conditions

OverweightObesity

Interventions

CagrilintidePlacebo cagrilintidePlacebo semaglutide

Study details

SPONSORNovo Nordisk A/S
START DATE2026-08-04

Related company profiles

Novo Nordisk

NVO

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT07745504
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record